NCT04519151 2023-06-08Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerSheba Medical CenterPhase 2 Recruiting24 enrolled
NCT02499952 2022-07-11Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell TumorsHoosier Cancer Research NetworkPhase 2 Terminated12 enrolled 14 charts